Cyclic AMP Enhances TGFβ Responses of Breast Cancer Cells by Upregulating TGFβ Receptor I Expression

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Oerlecke, Ilka ^a   Bauer, Elke ^a   Dittmer, Angela ^a   Leyh, Benjamin ^a   Dittmer, Jürgen ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FORSKOLIN; PROTEIN P21; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

ARTICLE; BREAST CANCER; CAMP GENE; CANCER CELL CULTURE; CANCER STEM CELL; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE INTERACTION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TGFBETA GENE; TGFBETAR1 GENE; TRANSCRIPTION REGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYCLIC AMP; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; FORSKOLIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESENCHYMAL STROMAL CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84872513077     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054261     Document Type: Article

References (63)

1. Ikushima H, Miyazono K, (2010) TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10: 415-424.
2. Massague J, (2008) TGFbeta in Cancer. Cell 134: 215-230.
3. Schmierer B, Hill CS, (2007) TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 8: 970-982.
4. Massague J, Seoane J, Wotton D, (2005) Smad transcription factors. Genes Dev 19: 2783-2810.
5. Bierie B, Moses HL, (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520.
6. Roberts AB, Wakefield LM, (2003) The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 100: 8621-8623.
7. Leivonen SK, Kahari VM, (2007) Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 121: 2119-2124.
8. Tang WJ, Gilman AG, (1992) Adenylyl cyclases. Cell 70: 869-872.
9. Sands WA, Palmer TM, (2008) Regulating gene transcription in response to cyclic AMP elevation. Cell Signal 20: 460-466.
10. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, et al. (2005) Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A 102: 4459-4464.
11. Son J, Lee JH, Kim HN, Ha H, Lee ZH, (2010) cAMP-response-element-binding protein positively regulates breast cancer metastasis and subsequent bone destruction. Biochem Biophys Res Commun 398: 309-314.
12. Chhabra A, Fernando H, Watkins G, Mansel RE, Jiang WG, (2007) Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis. Oncol Rep 18: 953-958.
13. Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, et al. (2007) PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J 26: 3534-3544.
14. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, et al. (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 1544-1549.
15. Dittmer A, Hohlfeld K, Lutzkendorf J, Muller LP, Dittmer J, (2009) Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10. Cell Mol Life Sci 66: 3053-3065.
16. Dittmer A, Schunke D, Dittmer J, (2008) PTHrP promotes homotypic aggregation of breast cancer cells in three-dimensional cultures. Cancer Lett 260: 56-61.
17. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, et al. (1992) TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71: 1003-1014.
18. Sun Y, Liu X, Eaton EN, Lane WS, Lodish HF, et al. (1999) Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling. Mol Cell 4: 499-509.
19. Micalizzi DS, Wang CA, Farabaugh SM, Schiemann WP, Ford HL, (2010) Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res 70: 10371-10380.
20. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, et al. (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197-206.
21. Dittmer A, Vetter M, Schunke D, Span PN, Sweep F, et al. (2006) Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells. J Biol Chem 281: 14563-14572.
22. Kalkhoven E, Roelen BA, de Winter JP, Mummery CL, van den Eijnden-van Raaij AJ, et al. (1995) Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 6: 1151-1161.
23. Lindemann RK, Ballschmieter P, Nordheim A, Dittmer J (2001) Transforming growth factor beta regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism. J Biol Chem 276: 46661-.
24. Lindemann RK, Nordheim A, Dittmer J, (2003) Interfering with TGFbeta-induced Smad3 nuclear accumulation differentially affects TGFbeta-dependent gene expression. Mol Cancer 2: 20.
25. Lei X, Bandyopadhyay A, Le T, Sun L, (2002) Autocrine TGFbeta supports growth and survival of human breast cancer MDA-MB-231 cells. Oncogene 21: 7514-7523.
26. Heaton JH, Dlakic WM, Dlakic M, Gelehrter TD, (2001) Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the Type-1 plasminogen activator inhibitor mRNA. J Biol Chem 276: 3341-3347.
27. Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, et al. (2010) The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Dev Cell 19: 831-844.
28. Zhao B, Wei X, Li W, Udan RS, Yang Q, et al. (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21: 2747-2761.
29. Yoo S, Lee YG, Kim JH, Byeon SE, Rho HS, et al. (2012) Cyclic adenosine monophosphate (cAMP)-induced histone hyperacetylation contributes to its antiproliferative and differentiation-inducing activities. Z Naturforschung C 67: 222-232.
30. Uccelli A, Moretta L, Pistoia V, (2008) Mesenchymal stem cells in health and disease. Nat. Rev. Immunol 8: 726-736.
31. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F, 3rd (2011) Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 29: 11-19.
32. Dittmer J, Oerlecke I, Leyh B (2011) Involvement of mesenchymal stem cells in cancer progression. In: Gunduz M, Gunduz E, editors. Breast Cancer- Focusing Tumor Microenvironment, Stem Cells and Metastasis. Rijeka, Croatia: Intech Open Access Publisher. 247-272.
33. Ditte P, Dequiedt F, Svastova E, Hulikova A, Ohradanova-Repic A, et al. (2011) Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res 71: 7558-7567.
34. Tarasewicz E, Jeruss JS, (2012) Phospho-specific Smad3 signaling: impact on breast oncogenesis. Cell Cycle 11: 2443-2451.
35. Hua F, Mu R, Liu J, Xue J, Wang Z, et al. (2011) TRB3 interacts with SMAD3 promoting tumor cell migration and invasion. J Cell Sci 124: 3235-3246.
36. Wu Q, Kim KO, Sampson ER, Chen D, Awad H, et al. (2008) Induction of an osteoarthritis-like phenotype and degradation of phosphorylated Smad3 by Smurf2 in transgenic mice. Arthritis Rheum 58: 3132-3144.
37. Cook SJ, McCormick F, (1993) Inhibition by cAMP of Ras-dependent activation of Raf. Science 262: 1069-1072.
38. Liu X, Sun SQ, Hassid A, Ostrom RS, (2006) cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in cardiac fibroblasts. Mol Pharmacol 70: 1992-2003.
39. del Valle-Perez B, Martinez-Estrada OM, Vilaro S, Ventura F, Vinals F, (2004) cAMP inhibits TGFbeta1-induced in vitro angiogenesis. FEBS Lett 569: 105-111.
40. Xing D, Bonanno JA, (2009) Effect of cAMP on TGFbeta1-induced corneal keratocyte-myofibroblast transformation. Invest Ophthalmol Vis Sci 50: 626-633.
41. Thalacker FW, Nilsen-Hamilton M, (1992) Opposite and independent actions of cyclic AMP and transforming growth factor beta in the regulation of type 1 plasminogen activator inhibitor expression. Biochem J 287: 855-862.
42. Schiller M, Dennler S, Anderegg U, Kokot A, Simon JC, et al. (2010) Increased cAMP levels modulate transforming growth factor-beta/Smad-induced expression of extracellular matrix components and other key fibroblast effector functions. J Biol Chem 285: 409-421.
43. Ragazzon B, Cazabat L, Rizk-Rabin M, Assie G, Groussin L, et al. (2009) Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells. Cancer Res 69: 7278-7284.
44. Chowdhury S, Howell GM, Rajput A, Teggart CA, Brattain LE, et al. (2011) Identification of a novel TGFbeta/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS One 6: e19335.
45. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL, (2012) Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 31: 552-562.
46. Ammanamanchi S, Brattain MG, (2004) Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells. J Biol Chem 279: 32620-32625.
47. Han J, Kim S, Yang JH, Nam SJ, Lee JE, (2012) TPA-induced p21 expression augments G2/M arrest through a p53-independent mechanism in human breast cancer cells. Oncol Rep 27: 517-522.
48. Dai M, Al-Odaini AA, Arakelian A, Rabbani SA, Ali S, et al. (2012) A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFbeta-mediated breast cancer cell migration and invasion. Breast Cancer Res 14: R127.
49. Li J, Karaplis AC, Huang DC, Siegel PM, Camirand A, et al. (2011) PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J Clin Invest 121: 4655-4669.
50. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, et al. (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446: 765-770.
51. Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T, (2006) Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res 66: 2067-2073.
52. Schmitt M, Harbeck N, Brunner N, Janicke F, Meisner C, et al. (2011) Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert rev Mol Diagn 11: 617-634.
53. Heldin CH, Moustakas A, (2012) Role of Smads in TGFbeta signaling. Cell Tissue Res 347: 21-36.
54. Heldin CH, Vanlandewijck M, Moustakas A, (2012) Regulation of EMT by TGFbeta in cancer. FEBS Lett 586: 1959-1970.
55. Beyer TA, Narimatsu M, Weiss A, David L, Wrana JL (2012) The TGFbeta superfamily in stem cell biology and early mammalian embryonic development. Biochim Biophys Acta. In press.
56. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
57. Badve S, Nakshatri H, (2012) Breast-cancer stem cells-beyond semantics. Lancet Oncol 13: e43-e48.
58. Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, et al. (2012) Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res 14: R100.
59. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
60. Hardt O, Wild S, Oerlecke I, Hofmann K, Luo S, et al. (2012) Highly sensitive profiling of CD44(+)/CD24(-) breast cancer stem cells by combining global mRNA amplification and next generation sequencing: Evidence for a hyperactive PI3K pathway. Cancer Lett 325: 165-174.
61. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, et al. (2011) Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 71: 614-624.
62. de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, et al. (2010) Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A 107: 6340-6345.
63. Scollen S, Luccarini C, Baynes C, Driver K, Humphreys MK, et al. (2011) TGF-beta signaling pathway and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev 20: 1112-1119.